The Danish National Genome Center (DNGC) has awarded a four-year contract to Lifebit, which will deploy its CloudOS to create a trusted federated research environment within the country’s supercomputing cluster. The technology would serve as a data management and analysis platform for researchers, clinicians and international collaborators in the country.
To learn more about the partnership and how it could help the DNGC (an agency and authority within the country’s healthcare system) in its mission to advance personalized medicine, Outsourcing-Pharma reached out to Thorben Seeger, Director of Business Development at Lifebit.
OSP: Could you please explain how you came to work with DNGC: did Lifebit collaborate with their team or any other entity under the Danish Healthcare umbrella?
TS: Lifebit is the world’s leading provider of Trusted Research Environment (TRE) software and infrastructure that enables data custodians (government and research organizations) to make their biomedical data securely findable and usable for data consumers (pharmaceutical and biotechnology companies). Examples of leading government and research organizations currently leveraging Lifebit’s technology include Genomics England, NIHR Cambridge Biomedical Research Campus and the Hong Kong Genome Institute.
On the pharmaceutical side, our latest partnership with Boehringer Ingelheim (BI) involves using our advanced transformation solutions and services to support the development of a data, analytics and infrastructure platform to leverage internal and external BI data assets. Boehringer Ingelheim has partnerships with biobanks and governments around the world – Lifebit’s federated technology will now allow them to gain a common view of these distributed datasets and jointly analyze these data, effectively helping them build cohorts much larger and more diverse. It will transform research and development for Boehringer Ingelheim, helping to build a world where access to biomedical data will never again be a bottleneck to curing disease.
Building on this recognized leadership position, Lifebit was presented as a recommended vendor by Deloitte, which consulted with the Danish government. Subsequently, Lifebit was invited to participate in an open tender commissioned by the DNGC through the EU Tender (TED) portal, which resulted in a recently announced partnership with the DNGC – a government agency and authority within of the Danish health system.
The DNGC was established in 2019 to implement the Danish government’s national personalized medicine strategy. for the organization. With its core vision of developing more accurate diagnostics, targeted treatments and strengthening research within the Danish healthcare system, DNGC selected Lifebit to provide a trusted federated research environment to realize this vision. This four-year contract will involve Lifebit deploying Lifebit CloudOS to create a trusted federated research environment within Denmark’s National Supercomputing Center.
This trusted federated research environment created by Lifebit CloudOS will allow researchers to collaborate on this rich data set at scale and drive international collaboration among other government initiatives. In addition, the federation will play a crucial role in enabling the DNGC to potentially collaborate with international partners such as Genomics England, France Genomique, Genomic Medicine Sweden and other biobanks around the world.
OSP: As you mentioned, the DNGC aims to develop more precise diagnostics, targeted treatments and improve its research efforts. Could you please share more details on how Lifebit’s technology will be leveraged to support this mission?
TS: The scale and sensitivity of genomic data pose unique challenges for storage, management, analysis, and collaboration. Lifebit’s patented federated technology allows data custodians, such as research organizations and biobanks, to virtually connect their datasets in federated systems. Importantly, it allows researchers to overcome the challenges of data access, sharing and collaboration, allowing DNGC researchers to access and analyze sensitive patient data at its source in a single environment. unified reliable search without moving the data.
Lifebit CloudOS will provide next-generation computing infrastructure within Denmark’s on-premises supercomputing center, enabling DNGC to establish, operate and collaborate globally with state-of-the-art national infrastructure for personalized medicine while now data security.
OSP: Does this data collaboration between Lifebit and DNGC have any initial or long-term goals or targets that you are looking to achieve?
TS: By democratizing access to population-scale clinical and genomic data, we are advancing precision medicine, enabling researchers to mine large datasets to find the most effective treatments for people with a particular genetic makeup. Initiatives such as the EU-wide PerMed EP, Genomics England and the DNGC are working together to usher in the transition to data-driven medicine.
True to the DNGC’s fundamental vision of strengthening research within the Danish healthcare system, the first phase of the strategy will involve the DNGC and its collaborators to recruit and sequence the whole genomes of 60,000 patients diagnosed with cancer, autoimmune diseases and rare diseases by 2024. there, the DNGC has a long-term vision to support the development of more accurate patient diagnosis and more precisely targeted treatment, with access to sequencing whole genome breakthrough and to develop a breakthrough research platform.
With the Danish National Center for Genomics, Denmark could have a state-of-the-art, state-of-the-art center for precision medicine. The DNGC is creating a supercomputer system that can combine large amounts of diverse data. For example, they can combine text from electronic health records (EHRs), x-rays, and genetic data. The analytical power of the supercomputer will uncover patterns and contexts that will provide a highly accurate picture of patient treatment while simultaneously providing health research with a data infrastructure that has great potential for the benefit of future patients.